CORE--DEVELOPMENTAL FACILITY

宾夕法尼亚- cfar发展核心的主要目标是通过为试点项目提供资金来源，促进宾夕法尼亚大学、费城儿童医院和Wistar研究所的艾滋病和艾滋病毒相关研究。发展核心基金将支持新兴艾滋病研究领域的短期（1年）项目，包括招募新研究人员的新研究、将注意力转向艾滋病的知名研究人员的研究，以及从事与以往工作有重大不同的艾滋病/艾滋病研究人员的研究。在提议的宾夕法尼亚- cfar的第一年，选择了四个项目作为资助：(1) J. Field博士关于HHV-8 (KSHV) G-蛋白偶联受体样分子（orf74）在该病毒介导的细胞转化中的作用的项目，(2)S. Isaacs博士开发一种表面表达重组抗原的牛瘟免疫系统的项目，(3)R. Ricciardi博士开发一种通过中断其聚合酶和加工因子之间的相互作用来筛选抑制HHV-8 DNA转录的化合物的方法，(4)博士的项目。Watkins和Behrman，并提出了一项关于艾滋病毒/艾滋病高发地区信息和资源代际转移的社会学建议。这些项目是从提交审议的26个项目中选出的。在提案的第2-5年，我们将根据(1)科学卓越性，(2)与艾滋病毒/艾滋病相关，以及(3)Penn-CFAR目标方面的计划平衡，每年选择4个项目。

The major goal of the Penn-CFAR Developmental core is the promotion of AIDS and HIV related research at the University of Pennsylvania, the Children's Hospital of Philadelphia, and the Wistar institute by providing a source of funding for pilot projects. The Developmental Core will support short term (1 year) projects in emerging areas of HIV research, including new research related to the recruitment of new investigators, research by established investigators who are turning their attention to AIDS, and research by AIDS/HIV investigators who are undertaking studies that represent a significant departure from their previous work. For year one of the proposed Penn-CFAR, four projects were chosen for funding: (1) a project by Dr. J. Field on the role of HHV-8 (KSHV) G- protein coupled receptor like molecule (Orf 74) on cell transformation mediated by this virus, (2) a project by Dr. S. Isaacs to develop a vaccinia immunization system with surface expression of the recombinant antigens, (3) a project by Dr. R. Ricciardi to develop a method for screening compounds that inhibit HHV-8 DNA transcription by interrupting the interaction between its polymerase and its processivity factor, and (4) a project by Drs. Watkins and Behrman and a proposal on the sociology of intergenerational transfer of information and resources in an area of high HIV/AIDS incidence. These projects were chosen from 26 submitted for consideration. For years 2-5 of the proposal we will select four projects each year based on (1) scientific excellence, (2) relevance to HIV/AIDS, and (3) programmatic balance in terms of the goals of the Penn-CFAR.